EGFR and cancer: bsTCEs targeting EGFR-positive cancer cells for γδ T cell-mediated death have been developed and have demonstrated efficacy in killing CRC cells while sparing EGFR+ keratinocytes, suggesting that this treatment may have a high therapeutic index in patients [24].